title: Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
abstract: OBJECTIVE
  Acromegaly has an important impact on quality of life (QOL). The aim of this study was to evaluate the associations of remission status and lanreotide treatment with QOL in patients with treated acromegaly, by the newly developed disease-generated acromegaly QOL questionnaire (ACROQOL).
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Fifty-two patients with treated acromegaly were recruited to complete the Chinese version of the ACROQOL translated and validated from the English version. These patients were divided into controlled and uncontrolled groups based on the latest remission criteria and further subdivided into four groups according to the present treatment with lanreotide or not. Comparisons between groups were analyzed.
  
  
  RESULTS
  There was no difference between controlled and uncontrolled groups in the ACROQOL scores of total score, both scales and psychological subscales. However, in the controlled group, present treatment with lanreotide, in comparison with no treatment, showed worse ACROQOL scores in total score (P = 0.021), psychological scale (P = 0.011), psychological subscale 'appearance' (P = 0.032) and 'personal relations' (P = 0.010).
  
  
  CONCLUSIONS
  The lanreotide treatment was negatively associated with QOL in biochemically controlled acromegalic patients, especially in the psychological aspect.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Chia-Yi Christian Hospital, No 539, Jhongsiao Road, Chiayi City, Taiwan.
authors.forename: Shih-Che
authors.initials: SC
authors.lastname: Hua
authors.forename: Yuan-Horng
authors.initials: YH
authors.lastname: Yan
authors.forename: Tien-Chun
authors.initials: TC
authors.lastname: Chang
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000523:psychology*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D012074:Remission Induction; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin